Level Biotechnology Inc. (3118) AI Stock Analysis

Level Biotechnology Inc.

(TPEx:3118)

Select Model

Rating:66Neutral

Price Target:TWD 33.00▲(9.45% Upside)

Action:initiatedcoverage

Date:11/10/26

The score is supported by a strong balance sheet, solid profitability, and attractive valuation. However, weak cash generation, inconsistent revenue growth, and bearish technical momentum materially limit the overall rating.

Positive Factors

Conservative Balance SheetMinimal leverage reduces financial risk and preserves flexibility for investment, dividends, or resilience during weaker trading periods. Steadily rising equity also supports the asset base, while healthy returns achieved without meaningful debt indicate efficient use of capital.

Negative Factors

Inconsistent Revenue MomentumAn uneven and recently contracting revenue base makes future earnings growth less predictable and increases dependence on margin discipline. Without sustained top-line expansion, the company may have less operating leverage and fewer resources to support reinvestment or absorb competitive pressure.

Level Biotechnology Inc. (3118) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 978.45M
Dividend Yield: 7.30%
Average Volume (3M): 16.76K
Price to Earnings (P/E): 12.8
Beta (1Y): 0.12
Revenue Growth: -3.54%
EPS Growth: 10.34%
Country: TW
Employees: 128
Sector: General
Sector Strength: 55
Industry: Biotechnology

Level Biotechnology Inc. Business Overview & Revenue Model

Company Description

Level Biotechnology Inc., founded in 1989 and based in New Taipei City, Taiwan, operates in the commercialization and distribution of scientific products and services. The company supplies specialized reagents and consumables for cell culture, immuno...

Level Biotechnology Inc. Financial Statement Overview

Summary

Strong profitability and a very low-leverage balance sheet are offset by weak, declining cash-flow conversion and inconsistent revenue growth.

Income Statement

72Positive

Balance Sheet

92Very Positive

Cash Flow

45Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	709.37M	736.59M	731.35M	660.61M	593.01M	677.28M
Gross Profit	243.83M	244.31M	237.13M	219.54M	202.59M	232.50M
EBITDA	110.31M	106.00M	102.62M	98.70M	93.00M	105.06M
Net Income	76.02M	79.70M	64.81M	62.91M	58.47M	68.18M
Balance Sheet
Total Assets	799.08M	866.80M	827.11M	822.67M	812.53M	787.62M
Cash, Cash Equivalents and Short-Term Investments	195.38M	210.34M	252.78M	467.41M	463.50M	472.95M
Total Debt	7.38M	7.98M	12.68M	13.50M	12.73M	13.36M
Total Liabilities	259.50M	286.63M	267.19M	273.20M	270.13M	242.78M
Stockholders Equity	539.58M	580.18M	559.91M	549.47M	542.40M	544.84M
Cash Flow
Free Cash Flow	77.98M	26.94M	-159.58M	62.54M	58.33M	146.79M
Operating Cash Flow	93.28M	59.61M	64.10M	70.21M	65.07M	155.95M
Investing Cash Flow	-18.10M	-38.93M	-216.10M	-10.90M	-10.19M	-8.79M
Financing Cash Flow	-134.79M	-63.12M	-62.70M	-55.40M	-64.34M	-54.52M

Level Biotechnology Inc. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:3118 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:3118	66Neutral	TWD 993.06M	12.83	―	7.30%	-3.54%	10.34%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4160	49Neutral	TWD 1.00B	52.56	―	4.93%	0.10%	-44.49%
TW:4171	40Underperform	TWD 896.99M	-40.49	―	―	11.99%	84.94%

* General Sector Average

Performance Comparison

TW:3118 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:3118	Level Biotechnology Inc.	30.15	-1.26	-4.00%
TW:4160	Genetics Generation Advancement Corp.	35.55	-16.18	-31.28%
TW:4171	GeneReach Biotechnology Corp.	15.50	-4.55	-22.69%
TW:6810	Bio Preventive Medicine Corp.	22.75	-1.35	-5.60%
TW:6879	Tci Gene Inc.	35.50	-3.65	-9.32%
TW:7725	LabTurbo Biotech Corporation	21.00	-1.81	-7.93%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Level Biotechnology Inc. AI Stock Analysis